TCON

TRACON Pharmaceuticals, Inc. [TCON] Stock Forecast

Q: What is TRACON Pharmaceuticals, Inc. stock symbol ?

TRACON Pharmaceuticals, Inc. is a US stock, located in San diego of Ca and trading under the symbol TCON

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

TCON Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

The Moving Average Convergence Divergence (MACD) for TCON recently turned positive (within last 10 days).

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 38.38%

EPS has been decreasing for the past 3 quarters (Quarter statements)

Currently unprofitable, and not expected to turn profitable in the coming year

Does not have any significance market cap ($15.29M)

TCON has less than 1 year of cash runway

Top 10 Correlated ETFs

TCON

Top 10 Correlated Stocks

TCON

In the News

08:00 08 Jun 2023 TCON

TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference

SAN DIEGO, June 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States, today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:30 am Eastern Time.

10:18 08 Jun 2023 TCON

TRACON Pharmaceuticals, Inc. (TCON) Q1 2023 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Edward White - H.C. Wainwright & Co., LLC Joel Beatty - Robert W.

09:11 08 Jun 2023 TCON

Why Is TRACON Pharma (TCON) Stock Down 51% Today?

TRACON Pharmaceuticals (NASDAQ: TCON ) stock is falling on Tuesday following an update on a legal battle with I-Mab (NASDAQ: IMAB ). The bad news for TCON stock comes from a legal ruling favoring I-Mab.

01:44 08 Jun 2023 TCON

Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade

Tracon (TCON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

08:00 08 Jun 2023 TCON

TRACON Pharmaceuticals, Inc. (TCON) Q4 2022 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Soumit Roy - Jones Research Joel Beatty - Robert W. Baird & Co. Robert Hazlett - BTIG Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Fourth Quarter and Year Ended 2022 Earnings Conference Call.

04:02 08 Jun 2023 TCON

TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2022 financial and operating results after the close of U.S. financial markets on Wednesday, March 8, 2023. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

01:52 08 Jun 2023 TCON

5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts

Analysts Say These Are Penny Stocks To Buy But Are They Worth The Risk? The post 5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

01:43 08 Jun 2023 TCON

Revisiting Tracon Pharmaceuticals

Today, we look back in on clinical stage developmental firm TRACON Pharmaceuticals for the first time since early 2021. The company's primary drug candidate Envafolimab could provide certain advantages over other approved PD-L1 inhibitors.

08:41 08 Jun 2023 TCON

TRACON Pharmaceuticals doses first patient in drug trial to treat malignant tumours

TRACON Pharmaceuticals Inc (NASDAQ:TCON) said it has dosed the first patient in a Phase 1/2 trial evaluating the company's CTLA-4 antibody, YH001, in combination with its PD-L1 antibody envafolimab and with doxorubicin, in front line therapy of patients with malignant tumours. The Phase 1/2 trial will assess the safety and efficacy of the triplet combination of YH001, envafolimab and doxorubicin in the common sarcoma sub-types of leiomyosarcoma and dedifferentiated liposarcoma, according to TRACON.

10:43 08 Jun 2023 TCON

TRACON Pharmaceuticals, Inc. (TCON) Q3 2022 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Joel Beatty - Robert W. Baird & Co. Edward White - H.C.

TCON Financial details

Company Rating

Neutral

Market Cap

15.29M

Income

-30.82M

Revenue

Book val./share

-0.47

Cash/share

0.28

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

08 Aug 2023

P/E

-0.48

Forward P/E

PEG

0.29

P/S

P/B

-1.35

P/C

2.15

P/FCF

-0.64

Quick Ratio

0.47

Current Ratio

0.5

Debt / Equity

-1.75

LT Debt / Equity

EPS (TTM)

-1.39

EPS next Y

EPS next Q

EPS this Y

-16.17%

EPS next Y

EPS next 5Y

783.45%

EPS last 5Y

-35.96%

Revenue last 5Y

-100%

Revenue Q/Q

EPS Q/Q

43.75%

SMA20

SMA50

-50%

SMA100

-50%

Inst Own

47.56%

Inst Trans

1.81%

ROA

-370%

ROE

673%

ROC

4.4%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

26.48M

Shs Float

14.55M

Target Price

52W Range

0.55-2.32

52W High

52W Low

RSI

Rel Volume

0.17

Avg Volume

188.13K

Volume

31.41K

Perf Week

-2.51%

Perf Month

-21.55%

Perf Quarter

-53.29%

Perf Half Y

-58.16%

Beta

1.35257

Volatility

0.01%, 0.05%

Prev Close

-4.37%

Price

0.6025

Change

-2.71%

TCON Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	1.11	0	0	0.02	0
Net income per share	-12.97	-7.46	-1.87	-1.67	-1.4
Operating cash flow per share	-11.42	-7.79	-1.9	-1.31	-1.25
Free cash flow per share	-11.42	-7.79	-1.9	-1.31	-1.26
Cash per share	14.51	5.41	4.02	1.4	0.83
Book value per share	7.96	0.89	2.79	0.68	-0.34
Tangible book value per share	7.96	0.89	2.79	0.68	-0.34
Share holders equity per share	7.96	0.89	2.79	0.68	-0.34
Interest debt per share	2.47	1.89	0.56	0.11	0.52
Market cap	16.98M	7.1M	105.11M	47.79M	31.17M
Enterprise value	-1.73M	-3.97M	77.51M	25.26M	23.54M
P/E ratio	-0.49	-0.31	-6.26	-1.66	-1.06
Price to sales ratio	5.66	0	0	138.12	0
POCF ratio	-0.55	-0.3	-6.17	-2.12	-1.19
PFCF ratio	-0.55	-0.3	-6.17	-2.11	-1.19
P/B Ratio	0.79	2.63	4.19	4.08	-4.36
PTB ratio	0.79	2.63	4.19	4.08	-4.36
EV to sales	-0.58	0	0	72.99	0
Enterprise value over EBITDA	0.05	0.18	-4.78	-0.89	-0.84
EV to operating cash flow	0.06	0.17	-4.55	-1.12	-0.9
EV to free cash flow	0.06	0.17	-4.55	-1.12	-0.9
Earnings yield	-2.06	-3.19	-0.16	-0.6	-0.94
Free cash flow yield	-1.81	-3.33	-0.16	-0.47	-0.84
Debt to equity	0.9	5.72	0.49	1.27	-3.72
Debt to assets	0.47	0.85	0.33	0.56	1.37
Net debt to EBITDA	0.54	0.5	1.7	0.79	0.27
Current ratio	3.01	1.46	3.5	1.82	0.81
Interest coverage	-150.39	-57.76	-29.77	-89.14	-28.06
Income quality	0.88	1.04	1.02	0.79	0.9
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	2.43	0	0	50.71	0
Research and developement to revenue	10.15	0	0	32.21	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	-0.14	0
Capex to depreciation	0	0	0.38	0.81	-0.24
Stock based compensation to revenue	0.89	0	0	5.13	0
Graham number	48.2	12.22	10.83	5.04	3.28
ROIC	3.61	1.51	0.57	1.07	1.45
Return on tangible assets	-0.86	-1.25	-0.45	-1.08	-1.51
Graham Net	7.38	0.33	2.65	0.53	-0.44
Working capital	27.11M	5.43M	26.37M	11.26M	-4.14M
Tangible asset value	21.44M	2.7M	25.07M	11.71M	-7.15M
Net current asset value	21.4M	1.84M	24.55M	10.09M	-8.39M
Invested capital	0.3	1.98	0.18	0.13	-1.37
Average receivables	0	0	0	0	0
Average payables	0	0	862.5K	3.33M	4.43M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-1.63	-8.4	-0.67	-2.45	4.1
Capex per share	0	0	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric	2022-03-31	2022-06-30	2022-09-30	2022-12-31	2023-03-31
Revenue per share	0	0	0	0	0
Net income per share	-0.48	-0.31	-0.3	-0.32	-0.46
Operating cash flow per share	-0.34	-0.4	-0.32	-0.21	-0.21
Free cash flow per share	-0.34	-0.4	-0.32	-0.21	-0.21
Cash per share	0.85	0.67	0.79	0.78	0.28
Book value per share	0.14	0.13	-0.12	-0.32	-0.47
Tangible book value per share	0.14	0.13	-0.12	-0.32	-0.47
Share holders equity per share	0.14	0.13	-0.12	-0.32	-0.47
Interest debt per share	0.04	0	0.43	0.48	0.05
Market cap	51.57M	40.54M	35.85M	33.22M	44.8M
Enterprise value	35.63M	26.96M	27.91M	25.59M	38.19M
P/E ratio	-1.36	-1.63	-1.38	-1.15	-1.03
Price to sales ratio	0	0	0	0	0
POCF ratio	-7.65	-5.06	-5.25	-7.14	-8.95
PFCF ratio	-7.64	-5.06	-5.25	-7.13	-8.95
P/B Ratio	18.48	15.95	-13.61	-4.65	-4.05
PTB ratio	18.48	15.95	-13.61	-4.65	-4.05
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-3.77	-4.34	-4.42	-4.39	-5.23
EV to operating cash flow	-5.28	-3.36	-4.09	-5.5	-7.63
EV to free cash flow	-5.28	-3.36	-4.08	-5.5	-7.63
Earnings yield	-0.18	-0.15	-0.18	-0.22	-0.24
Free cash flow yield	-0.13	-0.2	-0.19	-0.14	-0.11
Debt to equity	5.76	5.17	-8.46	-3.72	-1.75
Debt to assets	0.85	0.84	1.13	1.37	2.33
Net debt to EBITDA	1.69	2.19	1.26	1.31	0.9
Current ratio	1.16	1.17	1.53	0.81	0.5
Interest coverage	-363.31	-779.88	-109.95	-6.35	-6.16
Income quality	0.71	1.29	1.06	0.66	0.59
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0.15	-0.08	-0.11	-0.36	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	1.25	0.93	0.91	1.53	2.2
ROIC	0.66	0.28	0.45	0.31	1.91
Return on tangible assets	-0.5	-0.4	-0.33	-0.37	-1.31
Graham Net	0.03	0.02	-0.25	-0.41	-0.54
Working capital	2.34M	2.09M	6.26M	-4.14M	-7.04M
Tangible asset value	2.79M	2.54M	-2.64M	-7.15M	-11.07M
Net current asset value	1.22M	1.02M	-4.28M	-8.39M	-12.26M
Invested capital	0.25	0	-3.45	-1.37	0
Average receivables	0	0	0	0	0
Average payables	2.47M	5.5M	5.5M	1.96M	1.96M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-3.41	-2.44	2.46	1.01	0.98
Capex per share	0	0	0	0	0

TCON Frequently Asked Questions

What is TRACON Pharmaceuticals, Inc. stock symbol ?

TRACON Pharmaceuticals, Inc. is a US stock , located in San diego of Ca and trading under the symbol TCON

What is TRACON Pharmaceuticals, Inc. stock quote today ?

TRACON Pharmaceuticals, Inc. stock price is $0.6025 today.

Is TRACON Pharmaceuticals, Inc. stock public?

Yes, TRACON Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 188.13K
Market Capitalization 15.29M
Employee 18
CEO Dr. Charles P. Theuer M.D., Ph.D.
Headquarters San Diego,CA,US
IPO Date 2015-01-30
Website https://www.traconpharma.com

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.